Yellow wine polyphenolic compounds inhibit matrix metalloproteinase-2, -9 expression and improve atherosclerotic plaque in LDL-receptor-knockout mice

Journal of Pharmacological Sciences

Volumn 125, Issue 2, 2014, Pages 132-141

  Zhai, Xiaoya ^a,b   Chi, Jufang ^a   Tang, Weiliang ^a   Ji, Zheng ^a   Zhao, Fei ^a,b   Jiang, Chengjian ^a,b   Lv, Haitao ^a   Guo, Hangyuan ^a  

^a ZHEJIANG UNIVERSITY   (China)

^b WENZHOU MEDICAL UNIVERSITY   (China)

Author keywords

Atherosclerosis; Lipid lowering; Matrix metalloproteinase; Tissue inhibitor of matrix metalloproteinase; Yellow wine polyphenolic compound

Indexed keywords

CHOLESTEROL ESTER; GELATINASE A; GELATINASE B; INTERMEDIATE DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN RECEPTOR; POLYPHENOL; ROSUVASTATIN; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2; VERY LOW DENSITY LIPOPROTEIN; ANTILIPEMIC AGENT; FLUOROBENZENE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PYRIMIDINE DERIVATIVE; SULFONAMIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; CARDIOVASCULAR EFFECT; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DOWN REGULATION; DRUG DOSE COMPARISON; DRUG EFFECT; ENZYME ACTIVITY; ENZYME ASSAY; ENZYME INHIBITION; ENZYME REGULATION; HEART PROTECTION; IN VIVO STUDY; LIPID STORAGE; MALE; MOUSE; NONHUMAN; PROTEIN EXPRESSION; WINE; YELLOW RICE WINE; ANIMAL; C57BL MOUSE; DISEASE MODEL; DOSE RESPONSE; GENETICS; KNOCKOUT MOUSE; METABOLISM; PLAQUE, ATHEROSCLEROTIC; RICE;

ANIMALS; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FLUOROBENZENES; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPOLIPIDEMIC AGENTS; MALE; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MICE, INBRED C57BL; MICE, KNOCKOUT; ORYZA SATIVA; PLAQUE, ATHEROSCLEROTIC; POLYPHENOLS; PYRIMIDINES; RECEPTORS, LDL; SULFONAMIDES; TISSUE INHIBITOR OF METALLOPROTEINASE-1; TISSUE INHIBITOR OF METALLOPROTEINASE-2; WINE;

EID: 84904018837     PISSN: 13478613     EISSN: 13478648     Source Type: Journal    
DOI: 10.1254/jphs.13263FP     Document Type: Article

References (51)

1. Renaud S, de Lorgeril M. Wine, alcohol, platelets, and the French paradox for coronary heart disease. Lancet. 1992;339:1523-1526.
2. Gresele P, Cerletti C, Guglielmini G, Pignatelli P, de Gaetano G, Violi F. Effects of resveratrol and other wine polyphenols on vascular function: an update. J Nutr Biochem. 2011;22:201-211.
3. Leifert WR, Abeywardena MY. Cardioprotective actions of grape polyphenols. Nutr Res. 2008;28:729-737.
4. F Que, L Mao, X Pan. Antioxidant activities of five Chinese rice wines and the involvement of phenolic compounds. Food Research International. 2006;39:581-587. (Pubitemid 43374956)
5. Xie GF. [Functional constituents and health function of Chinese rice wine]. Liquor Making. 2008;11:76-77. (text in Chinese)
6. Xie GF, Xu R, Fan AP. [Analysis of components of Guyue Longshan rice wine benificial to health of heart and blood vessel system]. Liquor Making. 2011;38:64-66. (text in Chinese)
7. Guo H, Liu L, Shi Y, Sun A, Xu F, Chi J, et al. Chinese yellow wine and red wine inhibit matrix metalloproteinase-2 and improve atherosclerotic plaque in LDL receptor knockout mice. Cardiovasc Ther. 2010;28:161-168.
8. Guo H, Wang P, You B, Xing Y, Lee JD. Chinese yellow wine inhibits production of homocysteineinduced extracellular matrix metalloproteinase-2 in cultured rat vascular smooth muscle cells. Clin Nutr. 2007;26:348-354. (Pubitemid 46760479)
9. Mizoguchi H, Yamada K, Nabeshima T. Neuropsychotoxicity of abused drugs: involvement of matrix metalloproteinase-2 and -9 and tissue inhibitor of matrix metalloproteinase-2 in methamphetamine-induced behavioral sensitization and reward in rodents. J Pharmacol Sci. 2008;106:9-14. (Pubitemid 351159063)
10. Kuzuya M, Nakamura K, Sasaki T, Cheng XW, Itohara S, Iguchi A. Effect of MMP-2 deficiency on atherosclerotic lesion formation in apoE-deficient mice. Arterioscler Thromb Vasc Biol. 2006;26:1120-1125. (Pubitemid 43732121)
11. Wågsäter D, Zhu C, Björkegren J, Skogsberg J, Eriksson P. MMP-2 and MMP-9 are prominent matrix metalloproteinases during atherosclerosis development in the Ldlr(-/-)Apob(100/100) mouse. Int J Mol Med. 2011;28:247-253.
12. Satoh K, Takaguri A, Itagaki M, Kano S, Ichihara K. Effects of rosuvastatin and pitavastatin on ischemia-induced myocardial stunning in dogs. J Pharmacol Sci. 2008;106:593-599. (Pubitemid 351556238)
13. Chen J, Li D, Schaefer R, Mehta JL. Cross-talk between dyslipidemia and renin-angiotensin system and the role of LOX-1 and MAPK in atherogenesis studies with the combined use of rosuvastatin and candesartan. Atherosclerosis. 2006;184:295-301. (Pubitemid 43049713)
14. Arnaboldi L, Guzzetta M, Pazzucconi F, Radaelli G, Paoletti R, Sirtori CR, et al. Serum from hypercholesterolemic patients treated with atorvastatin or simvastatin inhibits cultured human smooth muscle cell proliferation. Pharmacol Res. 2007;56:503-508. (Pubitemid 350137771)
15. Cevik C, Otahbachi M, Nugent K, Warangkana C, Meyerrose G. Effect of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibition on serum matrix metalloproteinase-13 andtissue inhibitor matrix metalloproteinase-1 levels as a sign of plaque stabilization. J Cardiovasc Med (Hagerstown). 2008;9:1274-1278.
16. Luan Z, Chase AJ, Newby AC. Statins inhibit secretion of metalloproteinases-1, -2, -3, and -9 from vascular smooth muscle cells and macrophages. Arterioscler Thromb Vasc Biol. 2003;23:769-775. (Pubitemid 36566165)
17. Crisby M, Nordin-Fredriksson G, Shah PK, Yano J, Zhu J, Nilsson J. Pravastatin treatment increases collagen content and decreases lipid content, inflammation, metalloproteinases, and cell death in human carotid plaques. Circulation. 2001;103:926-933. (Pubitemid 32183796)
18. Wang Z, Ge J. Managing hypercholesterolemia and preventing cardiovascular events in elderly and younger Chinese adults: focus on rosuvastatin. Clin Interv Aging. 2014;9:1-8.
19. Guo H, Shi Y, Liu L, Sun A, Xu F, Chi J. Rosuvastatin inhibits MMP-2 expression and limits the progression of atherosclerosis in LDLR-deficient mice. Arch Med Res. 2009;40:345-351.
20. Napoli C, Balestrieri ML, Sica V, Lerman LO, Crimi E, De Rosa G, et al. Beneficial effects of low doses of red wine consumption on perturbed shear stress-induced atherogenesis. Heart Vessels. 2008;23:124-133. (Pubitemid 351494092)
21. Aji W, Ravalli S, Szabolcs M, Jiang XC, Sciacca RR, Michler RE, et al. L-arginine prevents xanthoma development and inhibits atherosclerosis in LDL receptor knockout mice. Circulation. 1997;95:430-437. (Pubitemid 27056211)
22. Ishibashi S, Goldstein JL, Brown MS, Herz J, Burns DK. Massive xanthomatosis and atherosclerosis in cholesterol-fed low density lipoprotein receptor-negative mice. J Clin Invest. 1994;93:1885-1893. (Pubitemid 24143065)
23. LIAO Gengjin, FU Jinfeng, LUO Pengfei. Calculation of a Meeh constant during thermal injury and pharmacology experiments in C57BL/6 mouse. Jiangsu Med J. 2011;37:1626-1628.
24. Frei B, Higdon JV. Antioxidant activity of tea polyphenols in vivo: evidence from animal studies. J Nutr. 2003;133:3275S-3284S. (Pubitemid 37222256)
25. Becker M, Rabe K, Lebherz C, Zugwurst J, Göke B, Parhofer KG, et al. Expression of human chemerin induces insulin resistance in the skeletal muscle but does not affect weight, lipid levels, and atherosclerosis in LDL receptor knockout mice on high-fat diet. Diabetes. 2010;59:2898-2903.
26. Kim A, Chiu A, Barone MK, Avino D, Wang F, Coleman CI, et al. Green tea catechins decrease total and low-density lipoprotein cholesterol: a systematic review and meta-analysis. J Am Diet Assoc. 2011;111:1720-1729.
27. Auger C, Caporiccio B, Landrault N, Teissedre PL, Laurent C, Cros G, et al. Red wine phenolic compounds reduce plasma lipids and apolipoprotein B and prevent early aortic atherosclerosis in hypercholesterolemic golden Syrian hamsters (Mesocricetus auratus). J Nutr. 2002;132:1207-1213. (Pubitemid 34606453)
28. Agouni A, Lagrue-Lak-Hal AH, Mostefai HA, Tesse A, Mulder P, Rouet P, et al. Red wine polyphenols prevent metabolic and cardiovascular alterations associated with obesity in Zucker fatty rats (Fa/Fa). PLos One. 2009;4:e5557.
29. Berrougui H, Grenier G, Loued S, Drouin G, Khalil A. A new insight into resveratrol as an atheroprotective compound: Inhibition of lipid peroxidation and enhancement of cholesterol efflux. Atherosclerosis. 2009;207:420-427.
30. Rosenblat M, Volkova N, Coleman R, Almagor Y, Aviram M. Antiatherogenicity of extra virgin olive oil and its enrichment with green tea polyphenols in the atherosclerotic apolipoprotein-E-deficient mice: enhanced macrophage cholesterol efflux. J Nutr Biochem. 2008;19:514-523. (Pubitemid 351952321)
31. Massaro M, Scoditti E, Carluccio MA, De Caterina R. Nutraceuticals and prevention of atherosclerosis: focus on ω-3 polyunsaturated fatty acids and mediterranean diet polyphenols. Cardiovasc Ther. 2010;28:e13-e19.
32. Zern TL, Fernandez ML. Cardioprotective effects of dietary polyphenols. J Nutr. 2005;135:2291-2294. (Pubitemid 41429579)
33. Natella F, Nardini M, Belelli F, Scaccini C. Coffee drinking induces incorporation of phenolic acids into LDL and increases the resistance of LDL to ex vivo oxidation in humans. Am J Clin Nutr. 2007;86:604-609. (Pubitemid 47435826)
34. Ajith TA, Riji T, Anu V. In vitro anti-oxidannt and DNA protective effects of the novel 3-hydroxy-3-methylglutaryl coenzyme A reduced inhibitor rosuvastatin. Clin Exp Pharmacol Physiol. 2008;35(5-6):625-629. (Pubitemid 351490097)
35. Ross R, Agius L. The process of atherogenesis: cellular and molecular interaction: from experimental animal models to humans. Diabetologia. 1992;35(suppl 2):S34-S40.
36. Kampoli AM, Tousoulis D, Papageorgiou N, Antoniades C, Androulakis E, Tsiamis E, et al. Matrix metalloproteinases in acute coronary syndromes: current perspectives. Curr Top Med Chem. 2012;12:1192-205.
37. Pasterkamp G, Schoneveld AH, Hijnen DJ, de Kleijn DP, Teepen H, van der Wal AC, et al. Atherosclerotic arterial remodeling and the localization of macrophages and matrix metalloproteases 1, 2 and 9 in the human coronary artery. Atherosclerosis. 2000;150:245-253. (Pubitemid 30336536)
38. Walter A, Etienne-Selloum N, Sarr M, de Kleijn DP, Teepen H, van der Wal AC, et al. Angiotensin II induces the vascular expression of VEGF and MMP-2 in vivo: preventive effect of red wine polyphenols. J Vasc Res. 2008;45:386-394.
39. Scoditti E, Calabriso N, Massaro M, Pellegrino M, Storelli C, Martines G, et al. Mediterranean diet polyphenols reduce inflammatory angiogenesis through MMP-9 and COX-2 inhibition in human vascular endothelial cells: a potentially protective mechanism in atherosclerotic vascular disease and cancer. Arch Biochem Biophys. 2012;527:81-89.
40. Konstantino Y, Nguyen TT, Wolk R, Aiello RJ, Terra SG, Fryburg DA. Potential implications of matrix metalloproteinase-9 in assessment and treatment of coronary artery disease. Biomarkers. 2009;14:118-129.
41. Gao D, Zhang X, Jiang X, Peng Y, Huang W, Cheng G, et al. Resveratrol reduces the elevated level of MMP-9 induced by cerebral ischemia-reperfusion in mice. Life Sci. 2006;78:2564-2570.
42. Tousoulis D, Andreou I, Tentolouris C, Antoniades C, Papageorgiou N, Gounari P, et al. Comparative effects of rosuvastatin and allopurinol on circulating levels of matrix metalloproteinases and tissue inhibitors of metalloproteinases in patients with chronic heart failure. Int J Cardiol. 2010;145:438-443.
43. Gao D, Zhang X, Jiang X, Peng Y, Huang W, Cheng G, et al. Resveratrol reduces the elevated level of MMP-9 induced by cerebral ischemia-reperfusion in mice. Life Sci. 2006;78:2564-2570.
44. Joshua D, Lambert, Chung S. Yang. Proceedings of the 3rd international scientific symposium on tea and human health: role of flavonoids in the diet. J Nutr. 2003;133:3244S-3318S.
45. Leroy V, Monier F, Bottari S, Trocme C, Sturm N, Hilleret MN, et al. Circulating matrix metalloproteinases 1, 2, 9 and their inhibitors TIMP-1 and TIMP-2 as serum markers of liver fibrosis in patients with chronic hepatitis C: comparison with PIIINP and hyaluronic acid. Am J Gastroenterol. 2004;99:271-279. (Pubitemid 38279869)
46. Vinson JA, Teufel K, Wu N. Red wine, dealcoholized red wine, and especially grape juice, inhibit atherosclerosis in a hamster model. Atherosclerosis. 2001;156:67-72. (Pubitemid 32429596)
47. Al-Awwadi NA, Bornet A, Azay J, Araiz C, Delbosc S, Cristol JP, et al. Red wine polyphenols alone or in association with ethanol prevent hypertension, cardiac hypertrophy, and production of reactive oxygen species in the insulin-resistant fructose-fed rat. J Agric Food Chem. 2004;52:5593-5597.
48. Kasdallah-Grissa A, Mornagui B, Aouani E, Hammami M, El May M, Gharbi N, et al. Resveratrol, a red wine polyphenol, attenuates ethanol-induced oxidative stress in rat liver. Life Sci. 2007;80:1033-1039. (Pubitemid 46204723)
49. Galati G, Lin A, Sultan AM, O'Brien PJ. Cellular and in vivo hepatotoxicity caused by green tea phenolic acids and catechins. Free Radic Biol Med. 2006;40:570-580. (Pubitemid 43170808)
50. Noll C, Raaf L, Planque C, Benard L, Secardin L, Petit E, et al. Protection and reversal of hepatic fibrosis by red wine polyphenols in hyperhomocysteinemic mice. J Nutr Biochem. 2011;22:856-864.
51. Bose M, Lambert JD, Ju J, Reuhl KR, Shapses SA, Yang CS. The major green tea polyphenol, (-)-epigallocatechin-3-gallate, inhibits obesity, metabolic syndrome, and fatty liver disease in high-fat-fed mice. J Nutr. 2008;138:1677-1683.